DUBLIN--(BUSINESS WIRE)--The "Anal Cancer - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.
Anal Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Anal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Anal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 10, 3 and 4 respectively.
Anal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Introduction
- Anal Cancer - Overview
- Anal Cancer - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Anal Cancer - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Anal Cancer - Companies Involved in Therapeutics Development
- Advaxis Inc
- Amgen Inc
- Atara Biotherapeutics Inc
- Bayer AG
- BeiGene Ltd
- Eli Lilly and Company
- Immunovaccine Inc
- ISA Pharmaceuticals BV
- Merck & Co Inc
- Ono Pharmaceutical Co Ltd
- Oryx GmbH & Co KG
- PDS Biotechnology Corp
- Sun Pharma Advanced Research Company Ltd
-
Taiwan Liposome Company Ltd
For more information about this report visit https://www.researchandmarkets.com/research/4vtslk/anal_cancer
